EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

Daiki Tokuyasu, Shigeaki Suzuki iD, Akiyuki Uzawa iD, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Takamichi Sugimoto, Kei Ishizuchi, Munenori Oyama, Manato Yasuda und 9 weitere

Annals of Clinical and Translational Neurology · 2024-05 · 11 (5) · 1338-1346

DOI: 10.1002/acn3.52051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 04.04.2024. Verfasst von Daiki Tokuyasu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Myasthenia Gravis, Antibodies, Monoclonal, Humanized, Complement Inactivating Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent analyses. The purpose of the present study was to evaluate the clinical significance of eculizumab and switching to ravulizumab for refractory AChR+ gMG patients in the real‐world experience.

Methods

Among the database of Japan MG registry survey 2021, we studied AChR+ gMG patients who received eculizumab. We also evaluated these patients who switched from eculizumab to ravulizumab. Responder was defined as an improvement of at least 3 points in MG‐ADL. We performed a questionnaire of preference between eculizumab and ravulizumab.

Results

Among 1,106 patients with AChR+ gMG, 36 patients (3%) received eculizumab (female 78%, mean age 56.0 years). Eculizumab was preferentially used in severe and refractory MG patients. The duration of eculizumab treatment was 35 months on average. MG‐ADL improved from 9.4 ± 4.9 to 5.9 ± 5.1, and 25 (70%) of the 36 gMG patients were responders. Postintervention status was markedly improved after the eculizumab treatment. Of 13 patients who did not continue eculizumab, 6 showed insufficiencies. Early onset MG was most effective. However, 15 patients switching from eculizumab to ravulizumab kept favorable response and tolerability. Questionnaire surveys showed preference for ravulizumab over eculizumab.

Interpretation

Eculizumab and switching to ravulizumab showed to be effective for refractory AChR+ gMG patients in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisAntibodies, Monoclonal, HumanizedComplement Inactivating AgentsHumansFemaleMaleMiddle AgedAgedAdultDrug SubstitutionRegistriesJapan

Substanzen

Antibodies, Monoclonal, HumanizedComplement Inactivating Agents

Autor:innen und Institutionen

  • Department of Neurology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
  • Department of Neurology, Tokyo Medical University, Tokyo, Japan.
  • Department of Neurology, Toho University Ohashi Medical Center, Tokyo, Japan.
  • Department of Clinical Laboratory and Biomedical Sciences, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan.

ORCID-Profile: Shigeaki Suzuki, Akiyuki Uzawa

Förderung

  • JSPS KAKENHI

Zitieren

APA

Tokuyasu, D., Suzuki, S., Uzawa, A., Nagane, Y., Masuda, M., Konno, S., Kubota, T., Samukawa, M., Sugimoto, T., Ishizuchi, K., Oyama, M., Yasuda, M., Akamine, H., Onishi, Y., Suzuki, Y., Kawaguchi, N., Minami, N., Kimura, T., Takahashi, M. P., …, & Utsugisawa, K. (2024). Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. Annals of Clinical and Translational Neurology, 11(5), 1338-1346. https://doi.org/10.1002/acn3.52051

Vancouver

Tokuyasu D, Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, et al. Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. Annals of Clinical and Translational Neurology. 2024;11(5):1338-1346. doi:10.1002/acn3.52051

BibTeX
@article{Tokuyasu2024,
  author = {Tokuyasu, Daiki and Suzuki, Shigeaki and Uzawa, Akiyuki and Nagane, Yuriko and Masuda, Masayuki and Konno, Shingo and Kubota, Tomoya and Samukawa, Makoto and Sugimoto, Takamichi and Ishizuchi, Kei and Oyama, Munenori and Yasuda, Manato and Akamine, Hiroyuki and Onishi, Yosuke and Suzuki, Yasushi and Kawaguchi, Naoki and Minami, Naoya and Kimura, Takashi and Takahashi, Masanori P and Murai, Hiroyuki and Utsugisawa, Kimiaki},
  title = {Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  volume = {11},
  number = {5},
  pages = {1338--1346},
  doi = {10.1002/acn3.52051}
}
Kostenlos starten →